KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.99

Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial.

Clément R Massonnaud, Maya Hites, Nathan Peiffer-Smadja, Jeanne Rancic, Yazdan Yazdanpanah, Sophie Luneau, Annabelle Dupont, Christelle Delmas, Jean-Luc Diehl, Aurélien Philippe, Sophie Susen, France Mentré, Florence Ader, David M Smadja, DisCoVeRy Study group

Angiogenesis 29(1) 8

PMID41353681
PMCIDPMC12682712
DOI10.1007/s10456-025-10023-7
发表日期2025-12-07
入排依据:记录类型属于综述、Meta 分析、社论、评论、病例或指南。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other。
摘要

摘要

BACKGROUND: Hydroxychloroquine (HCQ), long used for its immunomodulatory and vasculoprotective properties in autoimmune diseases such as antiphospholipid syndrome, was among the first drugs evaluated for COVID-19. Given the prominent endothelial dysfunction and coagulopathy in severe COVID-19, we investigated whether HCQ could modulate circulating biomarkers of vascular injury. METHODS: A longitudinal analysis comparing standard of care (SoC; n = 148) with HCQ plus SoC (n = 145) was conducted within the phase 3, multicenter, open-label, randomized, adaptive, controlled trial DisCoVeRy in hospitalized patients with COVID-19 (NCT04315948), which primary outcome was clinical status at day 15, measured by the WHO 7-point ordinal scale. Biomarkers of endothelial activation and coagulopathy-angiopoietin-2, P-selectin, and D-dimer-were measured on days 1, 3, 5, 8, and 11. Linear mixed-effects models assessed the influence of HCQ and baseline severity on biomarker trajectories. RESULTS: Severe disease at baseline was associated with higher biomarker levels: angiopoietin-2 (p < 10⁻⁵), P-selectin (p < 10⁻⁶), and D-dimer (p < 10⁻⁷). HCQ had no effect on angiopoietin-2 levels over time (0.002 95%CI: [- 0.003;0.007], p = 0.42). P-selectin increased significantly in both non-severe and severe SoC patients, but HCQ had no effect on the slope (0.005 95%CI: [- 0.001;0.012], p = 0.12). Regarding D-dimer, neither disease severity nor HCQ significantly affected the slope (- 0.004 95%CI: [- 0.016;0.009], p = 0.57 and - 0.000 95%CI: [- 0.009;0.009], p = 0.98, respectively). CONCLUSIONS: HCQ was not found to modify the longitudinal evolution of angiopoietin-2, P-selectin, or D-dimer in hospitalized patients with COVID-19. These findings confirm the absence of vascular benefit, reinforcing evidence against HCQ's clinical utility in COVID-19 and underscoring the need for alternative endothelial-targeted approaches.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Longitudinal trajectories of angiopoietin-2, P-selectin, and D-dimer levels in hospitalized COVID-19 patients according to baseline severity and treatment strategy. Panels A – C : Overall biomarker trajectories across all patients. Panels D – F : Biomarker levels stratified by baseline disease severity (moderate vs. severe). Panels G – I : Biomarker levels stratified by treatment (standard of care [SoC] vs. hydroxychloroquine [HCQ] + SoC). Panels J–L: Biomarker levels stratified by both baseline severity and treatment group. Values represent log10-transformed biomarker concentrations with mean ± 95% CI. Severe patients displayed significantly higher baseline angiopoietin-2, P-selectin, and D-dimer levels (all p < 10⁻⁵), but HCQ had no significant impact on biomarker trajectories compared with SoC (angiopoietin-2, p = 0.42; P-selectin, p = 0.12; D-dimer, p = 0.98). Raw units of angiopoietin-2: pg/mL; P-selectin: pg/mL; D-dimer: ng/mL
非 KM Figure